DDInter388 DDInter927
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Citalopram {u} (Compound) resembles {v} (Compound) Escitalopram
Citalopram {u} (Compound) treats {v} (Disease) alcohol dependence
Citalopram {u} (Compound) binds {v} (Gene) HTR2C
Citalopram {u} (Compound) upregulates {v} (Gene) PLS1
Citalopram {u} (Compound) palliates {v} (Disease) panic disorder
Citalopram {u} (Compound) downregulates {v} (Gene) RNH1
Citalopram {u} (Compound) causes {v} (Side Effect) Allergy aggravated
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Citalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Citalopram (Compound) resembles Escitalopram (Compound)
Citalopram (Compound) treats alcohol dependence (Disease)
Citalopram (Compound) binds HTR2C (Gene)
Citalopram (Compound) upregulates PLS1 (Gene)
Citalopram (Compound) palliates panic disorder (Disease)
Citalopram (Compound) downregulates RNH1 (Gene)
Citalopram (Compound) causes Allergy aggravated (Side Effect)
Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin